Standard BioTools Q1 2025 revenue $40.8M (-10% YoY); net loss $26.0M, adj EBITDA loss $16.9M

STANDARD BIOTOOLS INC.

2025-Q1 EPS reported -$0.07 revenue$40,795,000

First-quarter revenue $40.8M, down 10% YoY; consumables -16%, instruments +24%, services -16%.
Net loss $26.0M improved 19% YoY ($32.2M); adjusted EBITDA loss $16.9M improved 29%.
Non-GAAP gross margin 53.2%, down from 56.2% in Q1 2024 due to volume, mix, and pricing.
Cash & equivalents $260.7M, no material debt; FY2025 revenue outlook reaffirmed at $165-175M.
Operating expenses fell 38% YoY to $52.7M, driven by merger cost synergies and SBS productivity gains.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.